Gregory R. Blatt - Jun 21, 2022 Form 4 Insider Report for Vaxxinity, Inc. (VAXX)

Role: Director
Signature: /s/ Rene Paula Molina, attorney-in-fact for Gregory R. Blatt
Stock symbol: VAXX
Transactions as of: Jun 21, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/23/2022, 07:53 PM
Previous filing: Nov 18, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	VAXX	Class A common stock						623K	Jun 21, 2022	Held by Blatt Family Investments LLC	F1
holding	VAXX	Class A common stock						25.8K	Jun 21, 2022	Held by The Gregory R. Blatt 2020 Annuity Trust IX	F2
holding	VAXX	Class A common stock						265K	Jun 21, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VAXX	Stock option (right to buy)	Award	$0	+129K		$0.00	129K	Jun 21, 2022	Class A common stock	129K	$2.09	Direct	F3, F4, F5
holding	VAXX	Stock option (right to buy)						450K	Jun 21, 2022	Class A common stock	450K	$10.07	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are held by Blatt Family Investments LLC ("BFI"). The Reporting Person is the investment manager and a member of BFI, as well as the investment advisor of The Gregory R. Blatt 2018 GST Trust, which is also a member of BFI. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by BFI in which the Reporting Person has no pecuniary interest.
F2	These securities are held by The Gregory R. Blatt 2020 Annuity Trust IX. The Reporting Person is the sole trustee and the investment advisor with all investment authority.
F3	These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
F4	These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a "Change in Control" (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the issuer through the vesting date.
F5	These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.
F6	Represents 449,871 time-vesting options. These options are subject to a two-year vesting schedule, beginning on 7/28/2021, vesting in equal installments each month during the vesting period.